Burgdorf – Starting in the US from September 2014, the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide will be administered with the dual-chamber injection system Bydureon Pen, based on Ypsomed's LyoTwist® platform.
Lees meer... Ypsomed newly supplies AstraZeneca with the Bydureon Pen
Burgdorf – Annual general meeting of July 1, 2014.
Lees meer... Ypsomed increases dividends to shareholders by 50%
Burgdorf – Injection Systems and Diabetes Care to be managed separately.
Lees meer... Ypsomed strengthens sales in its business segments
Burgdorf – Ypsomed successfully implements turnaround strategy and signs three new Injection Systems contracts with GlaxoSmithKline (GSK), Palatin Technologies, Inc. and Pharmstandard.
Lees meer... Ypsomed 2013/14 business year: report and press release
Burgdorf – Simon Michel elected as successor of CEO Willy Michel.
Lees meer... Change in Ypsomed leadership